Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Maintenance therapy for inflammatory bowel disease.

Brian G Feagan1

  • 1Robarts Research Institute, The University of Western Ontario, London, Ontario, Canada.

The American Journal of Gastroenterology
|December 31, 2003
PubMed
Summary

Maintaining remission in inflammatory bowel disease (IBD) is crucial. Current therapies for Crohn's disease and ulcerative colitis have limitations, highlighting the need for better maintenance strategies and further research into effective treatments.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Efficacy and Safety of Etrasimod in Mildly to Moderately Active Ulcerative Colitis: Results From the Phase II GLADIATOR Trial.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2026
Same author

A decade of clinical data with vedolizumab: the past, present, and future.

Therapeutic advances in gastroenterology·2026
Same author

Pre-Crohn's Disease Stool From Discordant Siblings Promotes the Development of Colitis in Germ-Free Mice.

Gastroenterology·2026
Same author

Evaluating treatment to a target of transmural healing in patients with moderately to severely active Crohn's disease: rationale, design and protocol for the randomised controlled VECTORS trial.

BMJ open gastroenterology·2026
Same author

Association between endo-histological outcomes and colonic mucosal transcriptomic profiles in patients with ulcerative colitis receiving filgotinib.

Journal of Crohn's & colitis·2026
Same author

Design and rationale for the VICTRIVA study: A randomized, double-blind, phase 3b study of vedolizumab in combination with upadacitinib in Crohn's disease.

Contemporary clinical trials communications·2025

Area of Science:

  • Gastroenterology
  • Immunology
  • Pharmacology

Background:

  • Inflammatory bowel disease (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), poses significant challenges due to frequent disease recurrence after induction therapy.
  • Improved maintenance therapy is a critical unmet need in managing IBD.
  • Current maintenance strategies for CD and UC have varying efficacy and safety profiles.

Purpose of the Study:

  • To review randomized, controlled trials (RCTs) evaluating maintenance therapy for IBD.
  • To assess the evidence supporting current maintenance treatments for Crohn's disease and ulcerative colitis.
  • To identify gaps in knowledge and potential future directions for IBD maintenance therapy.

Main Methods:

  • Systematic review of randomized, controlled trials.

Related Experiment Videos

  • Analysis of data on maintenance therapy efficacy and safety in Crohn's disease and ulcerative colitis.
  • Evaluation of evidence for 5-aminosalicylates, antimetabolites, infliximab, purine metabolites, and probiotics.

    • Main Results:

    • 5-aminosalicylates lack strong evidence for Crohn's disease maintenance but are effective and safe for ulcerative colitis.
    • Antimetabolites and infliximab show moderate efficacy in high-risk Crohn's disease patients but carry risks of adverse effects.
    • Evidence supporting purine metabolites for ulcerative colitis maintenance is limited, while probiotics show promise.

    Conclusions:

    • Optimizing maintenance therapy for IBD remains a significant clinical challenge.
    • Further research is needed to establish evidence-based maintenance strategies, particularly for Crohn's disease.
    • Emerging therapies like probiotics warrant further investigation for ulcerative colitis maintenance.